Other

Vertex Pharmaceuticals·Income Statement·74 metrics

Breakdown

Loading...

Metrics

Capital Expenditures

Change in Accounts Receivable

Change in Other Liabilities

Other comprehensive income (loss), net of tax

Share-Based Payment Tax Withholding Decrease

Tax Withholding for Share-Based Payments

Change in Inventories

Change in Prepaid Expenses and Other Assets

Finance Lease Interest Paid

Finance Lease Principal Paid

Effect of Exchange Rate on Cash (Continuing Operations)

Net Change in Cash and Restricted Cash

Number of Operating Segments

Operating Lease Payments

ROU Asset Obtained - Operating Lease

Shares Issued for Share-Based Compensation

Shares Repurchased

OCI available-for-sale securities adjustment

OCI cash flow hedges

Other investing activities, net

Payments to acquire available-for-sale debt securities

OCI Available-for-Sale Securities, Tax

OCI Before Reclassifications, Net of Tax

Reclassification from AOCI, Net of Tax

OCI Cash Flow Hedge Gain (Loss), After Tax, Parent

Other Comprehensive Income (Loss)

OCI Attributable to Parent

Stock Repurchased During Period, Value

Software amortization expense

Common stock, number of votes per share

Maximum percentage of annual compensation contributed by the participant (percent)

Subpart F income, net of credits

Subpart F income, net of credits

Other

Deferred charges related to intra-entity transfers

Deferred charges related to intra-entity transfers

Effective Income Tax Rate Reconciliation, FDII, Amount

Effective Income Tax Rate Reconciliation, FDII, Percent

Non-deductible AIPR&D

U.S. tax on foreign earnings, net of credits

Changes in unrecognized tax benefits

Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount

Federal taxes

State taxes

Changes in unrecognized tax benefits

Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount

Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount

Increase in accrued expenses and other liabilities

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Investing Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Net payments due to CRISPR Therapeutics AG related to finite-lived intangible assets

Payments To Acquire Debt Securities, Available-For-Sale, Asset Acquisition

Proceeds From (Payments For) Finite-Lived Intangible Assets

Proceeds from sales and redemptions of investments in debt securities classified as available for sale

Proceeds from disposal of certain strategic investments

Cash received from option exercises

Property, Plant and Equipment, Gross, Period Increase (Decrease)

Reduction to finance leases

Granted (in shares)

Intrinsic value of stock options exercised

Granted (in shares)

Exercised (in shares)

Total stock-based compensation expense included in “Total costs and expenses”

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period

Issuance of common stock under benefit plans

Unrecognized tax benefits, settlements

Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation

Unrecognized tax benefits, deferred tax liabilities, gross

Interest expense and penalties, net (benefit)/charge recognized

Unrecognized tax benefits, increase (decrease) in deferred tax assets, gross

Foreign currency effect

Additions for tax positions of prior years

Increase (decrease) in amount of unrecognized tax benefits

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.